Trial · NCT03409107
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 96
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28) | Placebo | 0.19 | Standard Error 0.062 | Grams per deciliter | |
| Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28) | Daprodustat | 1.58 | Standard Error 0.061 | Grams per deciliter | |
| Percentage of Participants With Hemoglobin Increase of >=1.0 Grams Per Deciliter From Baseline to Evaluation Period | Placebo | 18 | Percentage of participants | ||
| Percentage of Participants With Hemoglobin Increase of >=1.0 Grams Per Deciliter From Baseline to Evaluation Period | Daprodustat | 77 | Percentage of participants | ||
| Change From Baseline in Short Form-36 (SF-36) Questionnaire Vitality Domain Score by Traditional Scoring at Week 28 | Placebo | 1.93 | Standard Error 1.161 | Scores on a scale | |
| Change From Baseline in Short Form-36 (SF-36) Questionnaire Vitality Domain Score by Traditional Scoring at Week 28 | Daprodustat | 7.29 | Standard Error 1.121 | Scores on a scale | |
| Percentage of Participants With Hgb Response (Hgb in the 11-12 Grams/Deciliter Range) During Evaluation Period (Week 24 to Week 28 Inclusive) | Placebo | 8 | Percentage of participants | ||
| Percentage of Participants With Hgb Response (Hgb in the 11-12 Grams/Deciliter Range) During Evaluation Period (Week 24 to Week 28 Inclusive) | Daprodustat | 52 | Percentage of participants | ||
| Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Hodges-Lehmann Estimate) | Placebo | 0.00 | Full Range 0.0 to 100.0 | Percentage of days | |
| Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Hodges-Lehmann Estimate) | Daprodustat | 53.59 | Full Range 0.0 to 100.0 | Percentage of days | |
| Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Mann-Whitney Estimate) | Placebo | 0.00 | Full Range 0.0 to 100.0 | Percentage of days | |
| Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Mann-Whitney Estimate) | Daprodustat | 53.59 | Full Range 0.0 to 100.0 | Percentage of days | |
| Change From Baseline in Post-randomization Hgb at Week 28 | Placebo | 0.20 | Standard Error 0.070 | Grams per deciliter | |
| Change From Baseline in Post-randomization Hgb at Week 28 | Daprodustat | 1.56 | Standard Error 0.069 | Grams per deciliter | |
| Rate of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria | Placebo | 18.88 | 95% Confidence Interval 12.33 to 27.66 | Events per 100 person year | |
| Rate of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria | Daprodustat | 1.33 | 95% Confidence Interval 0.16 to 4.82 | Events per 100 person year | |
| Change From Baseline by Domain and Single Item Scores on the Chronic Kidney Disease -Anemia Questionnaire (CKD-AQ) Symptom Questionnaire | Placebo | Tired/Low Energy/Weak Domain | 2.81 | Standard Error 1.132 | Scores on a scale |
| Change From Baseline by Domain and Single Item Scores on the Chronic Kidney Disease -Anemia Questionnaire (CKD-AQ) Symptom Questionnaire | Daprodustat | Tired/Low Energy/Weak Domain | 8.72 | Standard Error 1.086 | Scores on a scale |
| Change From Baseline by Domain and Single Item Scores on the Chronic Kidney Disease -Anemia Questionnaire (CKD-AQ) Symptom Questionnaire | Placebo | Chest Pain/Shortness of Breath Domain | 0.62 | Standard Error 0.971 | Scores on a scale |
| Change From Baseline by Domain and Single Item Scores on the Chronic Kidney Disease -Anemia Questionnaire (CKD-AQ) Symptom Questionnaire | Daprodustat | Chest Pain/Shortness of Breath Domain | 3.55 | Standard Error 0.932 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03409107/results